What an ELN connects to is the real buying test
November 5, 2026
This article explores why ELN connectivity is becoming a key consideration for biopharma organizations as adoption becomes widespread. It examines how fragmented ELN, LIMS, and laboratory data create manual handoffs, limit data reuse, and make it harder for scientists and AI applications to access experimental context. Genedata addresses this challenge by embedding its ELN in a shared data model that connects experiments with samples, molecules, process parameters, assay results, and broader biologics workflows, reducing data silos and creating a more integrated foundation for scientific research and AI-driven R&D.